Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

17.87 +0.13 (+0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,401,065
Open 17.65
Bid (Size) 17.87 (2)
Ask (Size) 17.88 (127)
Prev. Close 17.74
Today's Range 17.54 - 17.93
52wk Range 8.730 - 18.06
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
6 Analysts Assess Roivant Sciences: What You Need To Know
 
Via Benzinga
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits

Performance

YTD
+47.9%
+47.9%
1 Month
+19.6%
+19.6%
3 Month
+55.7%
+55.7%
6 Month
+78.0%
+78.0%
1 Year
+53.8%
+53.8%

More News

Read More
Why Roivant Sciences Stock Is Soaring Today
Via The Motley Fool
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
Via Benzinga
Wednesday's session: gap up and gap down stocks
Via Chartmill
A Glimpse of Roivant Sciences's Earnings Potential
Via Benzinga
What Does the Market Think About Roivant Sciences?
Via Benzinga
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease
Via Investor's Business Daily
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
From Roivant Sciences
Via GlobeNewswire
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
From Roivant Sciences
Via GlobeNewswire
Peering Into Roivant Sciences's Recent Short Interest
Via Benzinga
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
From Roivant Sciences
Via GlobeNewswire
Why Roivant Sciences Stock Bounced Back on Tuesday
Via The Motley Fool
Why Roivant Sciences Stock Was Slipping on Monday
Via The Motley Fool
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Via MarketMinute
Topics Economy Stocks
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For August 11, 2025
Via Benzinga
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
From Roivant Sciences
Via GlobeNewswire
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
From Pulmovant, Inc.
Via GlobeNewswire
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday?
Via Benzinga
Topics Government
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For May 29, 2025
Via Benzinga

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 17.87
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 10/21/25 04:00 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 12.37B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.